The U.S. Food and Drug Administration (FDA) has approved Kendrion Biopharma Inc.’s manufacturing facility in Bolognana, Italy, to produce RYPLAZIM. This plasma-derived human plasminogen is indicated for treating patients with plasminogen deficiency type 1 (PLGD-1), a rare and challenging chronic disease.   PLGD-1 primarily manifests through the development of abnormal extra-vascular fibrin-rich, ligneous lesions on mucosal surfaces throughout the body. The most commonly observed lesions occur ...